5-HT1D receptor agonists(Serotonin 1d (5-HT1d) receptor agonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersOther Diseases

Active Indication

Lennox Gastaut SyndromeEpilepsies, MyoclonicSeizures+ [7]

Inactive Indication

Drug Resistant EpilepsyLanger-Giedion Syndrome

Originator Organization

Zogenix, Inc.

Active Organization

UCB Pharma SAZogenix International Ltd.

UCB Trading (Shanghai) Co., Ltd.

+ [8]

Inactive Organization-

License Organization

Zogenix, Inc.Wyeth-Ayerst Laboratories

UCB Japan Co. Ltd.

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (25 Jun 2020),

Epilepsies, MyoclonicSeizures

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Priority Review (United States)

Structure/Sequence

Molecular FormulaC12H17ClF3N

InChIKeyZXKXJHAOUFHNAS-UHFFFAOYSA-N

CAS Registry404-82-0

Clinical Trials associated with Fenfluramine Hydrochloride

NCT07651293

/ Not yet recruitingNot ApplicableIIT

Using Fenfluramine to Test the Serotonin Deficiency Theory of Depression

Clinical depression is a common and disabling condition characterised by persistent low mood and loss of interest that interferes with daily functioning. Serotonin is a key brain neurotransmitter involved in mood regulation, and a leading theory proposes that depression is associated with impaired serotonin function (the serotonin deficiency hypothesis), which underpins the use of selective serotonin reuptake inhibitors (SSRIs) as first-line antidepressant treatments. However, the strength and specificity of the link between serotonin dysfunction and depressive symptoms in humans remains uncertain and requires direct evidence in living human brains.
Positron Emission Tomography (PET) allows in vivo quantification of neurotransmitter receptor systems using a radioactive tracer that binds to specific brain targets. The serotonin 2A receptor (5-HT2A) agonist tracer [11C]Cimbi-36 enables measurement of the active-state 5-HT2A receptor, which is highly expressed in cortical regions implicated in mood regulation. When combined with a pharmacological challenge that acutely increases serotonin levels, changes in [11C]Cimbi-36 binding can be used to estimate serotonin release capacity across different brain regions.
Previous work using an amphetamine challenge with [11C]Cimbi-36 has shown reduced serotonin release capacity in the frontal cortex of patients with depression compared with healthy controls, providing preliminary support for the serotonin deficiency hypothesis. However, amphetamine releases multiple neurotransmitters in addition to serotonin, limiting the ability to attribute these effects specifically to serotonergic dysfunction. Dl-fenfluramine is a more selective serotonin-releasing agent and therefore offers a targeted approach to probe serotonin release in the human brain.
This case-control observational study will compare serotonin release capacity between unmedicated adults with Major Depressive Disorder (MDD) and healthy control participants using dl-fenfluramine challenge combined with [11C]Cimbi-36 PET imaging. The primary objective is to test whether individuals with MDD show reduced fenfluramine-induced serotonin release, indexed by changes in [11C]Cimbi-36 binding, relative to healthy controls. Secondary objectives include exploring how multimodal imaging, blood biomarkers, and behavioural measures relate to serotonin release capacity and depressive symptom severity.
Following completion of imaging, participants with MDD who will start SSRI treatment as part of their usual clinical care will be followed for 8 weeks with remote assessments. The study will examine whether baseline measures of serotonin release capacity predict subsequent clinical response to SSRIs, defined primarily by change in clinician-rated depression scores over the treatment period. Together, these data aim to provide a more precise test of the serotonin deficiency hypothesis of depression and to identify potential biomarkers of SSRI treatment response in MDD.

Start Date01 Jul 2026

Sponsor / Collaborator

Imperial College Healthcare NHS Trust

[+1]

NCT07503444

/ Not yet recruitingPhase 3

A Phase 3 Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study With Open-Label Extension to Evaluate the Efficacy And Safety of Fenfluramine Hydrochloride in Study Participants With Rett Syndrome

The purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).

Start Date30 Jun 2026

Sponsor / Collaborator

UCB Biosciences, Inc.

NCT07555171

/ Enrolling by invitationNot ApplicableIIT

EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment

This study plans to learn if certain markers found during electroencephalogram (EEG) analysis could predict fenfluramine responsiveness to give clinicians greater insight into the effectiveness of fenfluramine in people with Lennox Gastaut Syndrome (LGS).

Start Date01 Apr 2026

Sponsor / Collaborator

The University of Chicago

[+1]

100 Clinical Results associated with Fenfluramine Hydrochloride

100 Translational Medicine associated with Fenfluramine Hydrochloride

100 Patents (Medical) associated with Fenfluramine Hydrochloride

3,042

Literatures (Medical) associated with Fenfluramine Hydrochloride

01 Sep 2026·JOURNAL OF PSYCHIATRIC RESEARCH

Comparative diagnostic accuracy of panic provocation tests: A meta-analysis

Review

Author: Iosifescu, Dan V ; Tural, Umit ; Shannon, Sara Rose

Panic provocation tests have been widely used to investigate the biological underpinnings of panic disorder (PD). However, their diagnostic specificity remains uncertain, as several agents can also induce panic-like reactions in healthy individuals. This meta-analysis estimated and compared diagnostic odds ratios (DORs) across different provocation methods. Random-effects meta-analyses were conducted using the Hartung-Knapp adjustment. Based on 123 studies including 5693 participants, sodium lactate infusion showed the highest pooled DOR (24.77, 95% CI 19.03-32.25, GRADE certainty = High), followed by isoproterenol (18.85, 95% CI 12.39-28.66, GRADE certainty = Moderate), cholecystokinin tetrapeptide (CCK-4; 15.03, 95% CI 7.83-28.84, GRADE certainty = Moderate), meta-chlorophenyl piperazine (m-CPP; 14.51, 95% CI 4.67-45.07, GRADE certainty = Low), caffeine (14.11, 95% CI 4.79-41.54, GRADE certainty = Moderate), hyperventilation (11.89, 95% CI 6.51-21.73, GRADE certainty = High), carbon dioxide inhalation (CO₂; 11.12, 95% CI 8.63-14.32, GRADE certainty = High), and yohimbine (7.87, 95% CI 1.12-55.13, GRADE certainty = Very low). Breath holding, fenfluramine and flumazenil did not demonstrate statistically significant discriminative ability. Meta-regression analysis confirmed that sodium lactate yielded significantly higher DORs than m-CPP, hyperventilation, CO₂, fenfluramine, flumazenil, and yohimbine. No substantial between-study heterogeneity or publication bias was identified across the pooled analyses. These findings suggest that provocation methods targeting acid-base balance, especially sodium lactate infusion, are associated with superior diagnostic discrimination between individuals with PD and healthy controls.

01 Aug 2026·EPILEPSY & BEHAVIOR

Efficacy and safety of fenfluramine in Dravet syndrome; A monocentric, observational study focused on initial dose, blood concentration, and reduction of concomitant medications

Article

Author: Mizutani, Satoshi ; Yabe, Manami ; Iguchi, Akihiro ; Imai, Katsumi ; Tsuyusaki, Yu ; Miyashita, Mitsuhiro ; Otani, Hideyuki ; Yamaguchi, Tokito

OBJECTIVE:

To evaluate the optimal initial dose, efficacy, and adverse events of fenfluramine (FFA) in the treatment of intractable epilepsy in Dravet syndrome (DS) in Japanese patients.

METHODS:

This single-center, observational study included Dravet patients treated with FFA. Information retrospectively collected from medical records included age, sex, concomitant antiseizure medications (including stiripentol [STP]), the initial and maximum dose of FFA, differences in the effects of FFA with and without STP, convulsive seizure frequency, adverse events, and FFA blood concentration.

RESULTS:

Of the 27 patients, 13 (48.1%) were male, and the median age was 14.9 years. After the initiation of FFA, 59.3% and 25.9% of patients were 50% and 90% responders, respectively. Of the sixteen 50% responders, 13 (81.3%) had either discontinued a concomitant antiseizure medication or were in the process of reducing the dose. In 88.9% of patients, the initial dose of FFA was less than 0.2 mg/kg/day, and ≥ 50% seizure reduction was achieved in 45.8% at less than 0.2 mg/kg/day. The effectiveness of FFA was not significantly different with or without STP. Among the ≥ 50% responders, cognitive and behavioral function improved in 9 (56.3%). The major adverse events were diarrhea (29.6%). No patients developed valvular heart disease or pulmonary artery hypertension. Among patients whose blood concentrations of FFA were measured, all 50% responders had < 80 ng/mL.

SIGNIFICANCE:

FFA effectively reduced convulsive seizures in DS even at low concentrations. we recommend the initiation of low-dose FFA, which may allow dose reduction or discontinuation of concomitant antiseizure medications in FFA responders.

01 Jul 2026·EPILEPSY & BEHAVIOR

Beyond seizure control: Functional and caregiver-reported outcomes of long-term fenfluramine treatment in Dravet syndrome

Article

Author: Veredice, Chiara ; Perulli, Marco ; Ascione, Federica ; Rosaria Chieffo, Daniela Pia ; Battaglia, Domenica Immacolata ; Massaroni, Valentina ; Contaldo, Ilaria ; Quintiliani, Michela ; Picilli, Maria ; Porto, Chiara ; Gambardella, Maria Luigia

OBJECTIVE:

To evaluate caregiver-reported perceptions of functional change during long-term fenfluramine (FFA) therapy in Dravet syndrome (DS) and to explore associations with cognitive, adaptive, and clinical variables.

METHODS:

This single-center, cross-sectional study included 21 individuals with DS (mean age 16.1 ± 7.2 years; 62% female) receiving FFA as adjunctive therapy for a median of 3.0 years (IQR 2-6). Standardized cognitive and adaptive assessments (WISC-IV, WAIS-IV, Leiter-R, Vineland-II) were combined with a purpose-designed 13-item caregiver questionnaire evaluating perceived changes across communication, attention, behavior, and daily functioning (Likert 1-5; Cronbach's α = 0.83). Non-parametric statistics were used to explore associations with seizure outcomes and clinical predictors.

RESULTS:

Over the previous 12 months, 52.4% achieved ≥ 50% seizure reduction and 19.0% were seizure-free. Standardized tests confirmed profound cognitive and adaptive impairment (IQ range 39-51; Vineland composite median = 20), consistent with floor effects. In contrast, caregivers reported consistent functional improvements in expressive language, attention, environmental alertness, and behavioral regulation (median global improvement = 4 [IQR 4-5]). Younger age (ρ = -0.48, p = 0.029) and higher rehabilitation frequency (ρ = 0.50, p = 0.022) were associated with greater perceived improvement, whereas earlier seizure onset predicted poorer outcomes (ρ = -0.52, p = 0.015).

SIGNIFICANCE:

Despite severe baseline impairment, caregivers perceived ecologically meaningful functional gains during long-term FFA therapy. Functional improvements did not strictly parallel seizure reduction, suggesting broader neuromodulatory and developmental effects. Findings highlight the need to integrate caregiver-informed measures with standardized assessments and to combine pharmacological and rehabilitative strategies to optimize outcomes in DS.

PLAIN LANGUAGE SUMMARY:

This study explored how caregivers of people with Dravet syndrome perceived everyday changes during long-term treatment with fenfluramine. Although standard tests confirmed severe cognitive and adaptive impairments, caregivers noticed meaningful improvements in communication, attention, alertness, and behavior. These changes were more evident in younger patients and in those receiving regular rehabilitation. Importantly, improvements were reported even when seizures did not markedly decrease, suggesting that fenfluramine may have broader effects on brain function beyond seizure control. Combining medication with early and continuous rehabilitative care may help maximize quality of life for individuals with Dravet syndrome and their families.

News (Medical) associated with Fenfluramine Hydrochloride

01 May 2026

·pmlive.com

UCB presentation highlights impacts of epilepsy on daily life

UCB has presented new data at the American Academy of Neurology Annual Meeting 2026 highlighting the impact of epilepsy on quality of life for both patients and caregivers. The findings include interim survey results in developmental and epileptic encephalopathies (DEEs), showing that more than a quarter of patients experience daily sleep disturbances. These were linked to temporary loss of activities of daily living (ADLs) and communication in a significant proportion of cases. Andrea Wilkinson, UCB Global Head of Patient Engagement and Advocacy and lead author of the study, said: “These results demonstrate the clear relationship between disrupted sleep and temporary losses in daily function and communication, underscoring the importance of addressing disease impacts beyond seizure alone.” Additional real-world data showed that prolonged seizures affect the ability to carry out everyday activities, with 88% of patients and 96% of caregivers reporting disruption. Seizures were also associated with reduced work productivity and increased anxiety and depression among both groups. A subgroup analysis of patients experiencing prolonged seizures found higher use of healthcare resources compared with non-prolonged events, including increased hospitalisations, emergency visits and ambulance use. Separate data presented at the meeting evaluated treatment persistence with fenfluramine in people with Lennox-Gastaut syndrome (LGS) in the USA. The analysis indicated reductions in use of healthcare resources and antiseizure medication burden among patients who remained on treatment. Fenfluramine showed decreases in in-patient hospitalisation claims, emergency room visits and ambulance use among patients for whom there was 12 months of continuous treatment data available. Treatment persistence was reported at 73% at six months and 61% at 12 months. UCB said the findings reflect the broader burden of epilepsy beyond seizure control, including impacts on daily functioning, mental health and healthcare use. “Families living with LGS manage far more than seizures alone. Fewer emergency room visits, hospitalizations, and ambulance use can translate into less disruption, fewer crises and more stability for families,” said UCB Head of US Medical Neurology, Hugo Xi. He added that the ongoing, persistent use of the treatment helped reinforce available evidence that such therapy was compatible with patients’ real-life situations. UCB presented a total of 21 abstracts at the meeting. Two-thirds focussed on epilepsy, with the remainder devoted to rare neurological conditions, including six myasthenia gravis (MG) abstracts.

Clinical Result

20 Apr 2026

·www.biospace.com

UCB elevates epilepsy expertise with up to $1.15B Neurona takeover

The acquisition of Neurona will put UCB in both the epilepsy and cell therapy space, even as many of its fellow pharmas move away from the latter modality. UCB is fronting $650 million to absorb California-based Neurona Therapeutics to deepen its epilepsy portfolio and expand into regenerative medicine. As part of the acquisition agreement, announced Friday afternoon, UCB will also put up to $500 million on the line in milestone payments. The companies expect to consummate the transaction by the end of the second quarter, pending all necessary clearances. The buyout’s centerpiece is NRTX-1001, an investigational cell therapy undergoing Phase 1/2 development for drug-resistant unilateral and bilateral mesial temporal lobe epilepsy (MTLE). The medicine is meant to be a single-dose treatment, administered directly into the brain via a minimally invasive procedure, that delivers cells that produce the neurotransmitter gamma-aminobutyric acid. This mechanism could rebalance overall neural networks in patients with epilepsy and potentially reduce the frequency of seizures, UCB said on Friday. Initial Phase 1/2 data presented in December showed that the cell therapy resulted in an up to 89% median reduction in debilitating seizures seven to 12 months after administration. The study has a primary completion date of June 2027. “For more than 30 years, UCB has helped shape the modern epilepsy landscape,” UCB CEO Jean-Christophe Tellier said in a prepared statement on Friday. “Bringing NRTX‑1001 into our portfolio allows us to extend that legacy into the era of regenerative medicine.” The asset, Tellier continued, “has the potential to provide durable targeted repair of the nervous system.” Friday’s acquisition agreement falls in line with UCB’s strategy to lean into its epilepsy expertise. In January 2022, the company bet up to $1.9 billion to swallow Zogenix and its serotonergic drug Fintepla, indicated for seizures in patients with Dravet syndrome and Lennox-Gastaut syndrome. In 2025, Fintepla made €427 million (around $501 million) worldwide in net sales, a 30% year-on-year increase. UCB’s epilepsy portfolio is led by Briviact, which last year grew 14% to earn €758 million (approximately $890 million). The Neurona acquisition also signals UCB’s belief in the cell therapy modality despite some recent high-pro In October 2025, for instance, Takeda announced that it would no longer invest in cell therapies, and Novo Nordisk followed just days later. Several companies have since reaffirmed their commitment to the cell therapy space, including Oryon Cell Therapies and Stylus Medicine. The space is led by Gilead, which just this year has pumped billions into its cell capacities with the acquisition of CAR T partner Arcellx for $7.8 billion. The content above comes from the network. if any infringement, please contact us to modify.

Cell TherapyAcquisitionImmunotherapyClinical Study

19 Apr 2026

·endpoints.news

UCB plots epilepsy expansion with $650M Neurona cell therapy acquisition

UCB plans to pay $650 million for Neurona Therapeutics in a bid to broaden its clinical-stage epilepsy portfolio. The deal comes with as much as $500 million in milestone payments. Neurona is developing a treatment called NRTX-1001 for drug-resistant mesial temporal lobe epilepsy. CEO Cory Nicholas told Endpoints News a year ago that the FDA has signed off on a Phase 3 trial that could be used for approval. The cell therapy has already been in an open-label Phase 1/2 study and shown promise in the first handful of patients. The potential total deal value of $1.15 billion extends the growing list of billion-dollar tuck-in deals that biopharmas have been lining up for next-generation molecules to take them into the next decade. UCB’s last big acquisition was in 2022, when it dished out $1.9 billion to get a different epilepsy medication, Fintepla, as part of its Zogenix buyout . “For more than 30 years, UCB has helped shape the modern epilepsy landscape. Bringing NRTX‑1001 into our portfolio allows us to extend that legacy into the era of regenerative medicine,” UCB CEO Jean-Christophe Tellier said in a press release . As a private company, it’s unclear how big of a return Neurona’s investors will get. The startup has raised at least $385 million during its decade-long history, including $120 million last year . Well-known investors include The Column Group, Cormorant Asset Management, Viking Global Investors and Fidelity. The pluripotent stem cell-derived therapy aims to help patients who don’t respond to current epilepsy medications. Those patients sometimes have to resort to getting pieces of their brain removed through a temporal lobectomy . “Unfortunately, these are still medieval options that aren’t very good ones for people because of the destructiveness,” Nicholas previously told Endpoints. NRTX‑1001 seeks to restore malfunctioning neural circuitry by delivering cells that help make a key inhibitory neurotransmitter known as GABA. The therapy is given as a single dose directly into the brain, and the cells are “intended to persist for life,” Nicholas previously said. “When they’re stimulated by a seizure, it turns on the administered NRTX cells to secrete a proportional amount of the GABA to quiet the seizure, and after it quenches the seizure, it essentially turns itself off,” the CEO said. Nicholas and his team, which stood at 90 employees as of a year ago, also had ambitions of getting into other forms of epilepsy beyond the temporal lobe, as well as other neurological conditions such as traumatic brain injury, Alzheimer’s, Parkinson’s and more. The biotech was founded in 2015 based on work from scientists at the University of California, San Francisco. The deal with UCB is expected to close by the end of this quarter.

AcquisitionCell TherapyPhase 3

100 Deals associated with Fenfluramine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04148	Fenfluramine Hydrochloride	A08AA02	DB00574

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lennox Gastaut Syndrome	European Union	UCB Pharma SA	20 Apr 2023
Lennox Gastaut Syndrome	Iceland	UCB Pharma SA	20 Apr 2023
Lennox Gastaut Syndrome	Liechtenstein	UCB Pharma SA	20 Apr 2023
Lennox Gastaut Syndrome	Norway	UCB Pharma SA	20 Apr 2023
Epilepsies, Myoclonic	United States	UCB, Inc.	25 Jun 2020
Seizures	United States	UCB, Inc.	25 Jun 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	NDA/BLA	Canada	UCB Pharma GmbH	01 Nov 2025
Rett Syndrome	Phase 3	United States	UCB Trading (Shanghai) Co., Ltd.	26 Jun 2026
Rett Syndrome	Phase 3	United States	UCB Pharma SA	26 Jun 2026
Rett Syndrome	Phase 3	China	UCB Trading (Shanghai) Co., Ltd.	26 Jun 2026
Rett Syndrome	Phase 3	China	UCB Pharma SA	26 Jun 2026
Rett Syndrome	Phase 3	Japan	UCB Trading (Shanghai) Co., Ltd.	26 Jun 2026
Rett Syndrome	Phase 3	Japan	UCB Pharma SA	26 Jun 2026
Rett Syndrome	Phase 3	Argentina	UCB Pharma SA	26 Jun 2026
Rett Syndrome	Phase 3	Argentina	UCB Trading (Shanghai) Co., Ltd.	26 Jun 2026
Rett Syndrome	Phase 3	Australia	UCB Trading (Shanghai) Co., Ltd.	26 Jun 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03936777 (CTgov)	Phase 3	Seizures \| Epilepsies, Myoclonic \| Lennox Gastaut Syndrome	412	ZX008	mutgcxgnhi = aedozckkdc doeyfefmgj (mclewcltit, qbabwsyles - mnxsavwzom) View more	-	17 Nov 2025
P12-9.002 (AAN2025)	Not Applicable	Epilepsies, Myoclonic	1,043	Fenfluramine	zmwehzlvhu(xwxwfkxtkz) = an encouraging SMR cvndvwvtbj (dmldvoxynb )	-	07 Apr 2025
S12.002 (AAN2025)	Not Applicable	Cardiovascular Diseases	3,563	Fenfluramine Oral Solution	vdzofofnmx(mxnbgtyhgf) = qfcgepgtfj ygozvldbqh (pfgnntbmuz )	Positive	07 Apr 2025
NCT03355209 (P8-9.002, AAN2025)	Phase 3	Lennox Gastaut Syndrome	247	Fenfluramine 0.2 mg/kg/day	jspmufhpym(vyrccjpega) = 16.2% ywxmlrkjnb (vzlumrgzoe ) View more	Positive	07 Apr 2025
NCT03467113 (P9-9.010, AAN2025)	Phase 1	Epilepsies, Myoclonic \| Lennox Gastaut Syndrome	9	Fenfluramine	valzhagdis(eqjkkwefhy) = iziixhpxay rfbbirttmb (smvcogtmix, 4 - hours post to dose) View more	Positive	07 Apr 2025
NCT03467113 (P9-9.010, AAN2025)	Phase 1	Epilepsies, Myoclonic \| Lennox Gastaut Syndrome	9	Cannabidiol	valzhagdis(eqjkkwefhy) = ebmaavtdyx rfbbirttmb (smvcogtmix, 2 - hours post to dose) View more	Positive	07 Apr 2025
PRNewswire Manual	Phase 3	Epilepsies, Myoclonic	324	FINTEPLA	ifypbdyrzv(bpyrummame) = dnsytzyvpr sdaslmrphv (hnooqvnthu ) View more	Positive	12 Mar 2025
NCT03299842 (CTgov)	Phase 3	Seizures \| Epilepsies, Myoclonic	5	ZX008 (Fenfluramine Hydrochloride)	uwigizhmri(lhgectrvmx) = frdmxaypwf wnqytoyfir (ydfmkjhspx, vspabietgb - hbqusajxua) View more	-	13 Nov 2023
NCT03861871 (CTgov)	Phase 2	CDKL5 Deficiency Disorder \| Craniodiaphyseal Dysplasia	7	Fenfluramine Hydrochloride	wcuujfwxmh(hmaeipdckd) = qcepxyzaau yevgmggofm (bqeyhdcesa, 122.44) View more	-	04 Oct 2023
phase 3 clinical trial (Pubmed \| Epilepsia)	Phase 3	Epilepsies, Myoclonic	143	Placebo	rpfsmzmqug(gkzbozfyfx) = qokhrsidwv ancrrebjgm (suedcufoev ) View more	Positive	01 Oct 2023
phase 3 clinical trial (Pubmed \| Epilepsia)	Phase 3	Epilepsies, Myoclonic	143	Fenfluramine .7 mg/kg/day	rpfsmzmqug(gkzbozfyfx) = mvrpxwnkkj ancrrebjgm (suedcufoev ) View more	Positive	01 Oct 2023
NCT02823145 (Study 1504 \| 4684, CTgov)	Phase 3	Epilepsies, Myoclonic	375	ZX008	rbhknhagrt = dmzsvvppbt mycgzzpucd (bdhfyzkonz, ybxulmjbqe - datohpxinf) View more	-	25 Sep 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis